Skip to main content

Table 1 Characteristics, details of interventions used and outcomes measured in randomized trials studying albumin treatment during spontaneous bacterial peritonitis, sepsis other than SBP in cirrhotic patients and general ICU population with sepsis

From: Albumin infusion in spontaneous bacterial peritonitis: another brick off the wall?

Trial N Age, ya Experimental treatment Control treatment Mortality (albumin vs. control group; p)
Spontaneous bacterial peritonitis
Sort et al. [8] 126 61.0 (7.9) 20% albumin No vascular filling Favors albumin
(22% vs. 41%; p = 0.03)b
Xue et al. [10] 112 22–70 20% albumin No vascular filling Favors albumin
(10% vs. 34%; p = 0.002)c
Fernandez et al. [14] 20 61.0 (9.5) 20% albumin 6% HES 200/0.5 NS (not significant)
(0% vs. 20%; p = 0.47)c
Chen et al. [11] 30 56.5 (11.5) 20% albumin No vascular filling NS
(26.7% vs. 40%; p = 0.70)c
Sepsis other than SBP in cirrhotic patients (no septic shock)
Guevara et al. [15] 97 56 (11) 20% albumin No vascular filling NS
(17% vs. 20%; p = 0.78)b
Thévenot et al. [16] 193 55.3 (8.6) 20% albumin No vascular filling NS
(30% vs. 22%; p = 0,16)b
Sepsis and septic shock in general ICU population d
SAFE study [2]e 1218 60.5 (17.2) 4% albumin NaCl 0.9% NS
(30.7% vs. 35.3%; p = 0.09)f
ALBIOS study [3] 1810 69 [59–77] 20% albumin Crystalloids NS
(20.9% vs. 21.1%; p = 0.87)f
  1. aMean (SD) or median [IQ] or range
  2. b3-month mortality
  3. cHospital mortality
  4. dOnly studies including more than 100 patients are presented
  5. ePredefined subgroup of patients with severe sepsis from the SAFE study
  6. f28-day mortality